Real-world study of genetic types in advanced thyroid cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced thyroid cancer that cannot be removed by surgery, or it has come back or spread.
- Your specific type of thyroid cancer is one of these: radioiodine-refractory, not suitable for iodine therapy, medullary, poorly differentiated, or anaplastic.
- You have already had genetic testing done on your tumor to look for cancer-related genes or treatment targets.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving targeted drugs before surgery can help shrink advanced thyroid cancers, making them easier to remove. It uses your tumor's genetic profile to choose the best treatment for you.
This study tests whether giving treatment before surgery (neoadjuvant therapy) helps people with locally advanced thyroid cancer. It aims to shrink the tumor so surgery can be more successful.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
This trial tests two oral medications, avutometinib and defactinib, for people with advanced thyroid cancer that has specific genetic changes. The goal is to see if these drugs can shrink tumors or slow their growth.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Hear when a new Advanced Thyroid Cancer Patients Who Received Target Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.